文献速递乳腺技术与安全MR

评估跨软件平台的乳腺癌体素内不相干运动MRI生物标志物

Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms.
PubMed 文献 · Radiol Imaging Cancer · 2025-01-01

这项两中心回顾性研究纳入106例患者(18个良性、88个恶性病灶),比较两款软件(Igor与Firevoxel)导出的IVIM参数及其影像组学特征对乳腺癌的鉴别价值,组织扩散系数软件间一致性最高(变异系数4.8%与2.8%),多参数联合模型AUC达0.90±0.03与0.84±0.04。

要点

  • 组织扩散系数(Dt)跨软件一致性最高,两中心变异系数分别为4.8%和2.8%。
  • 灌注分数(fp)与伪扩散系数(Dp)跨软件一致性较低,变异系数最高达36.9%。
  • 多参数联合模型鉴别乳腺良恶性病灶的AUC最高为0.90±0.03。

核心结论

  • 本研究证实IVIM生物标志物用于乳腺癌特征描述具有转化潜力。

研究设计与样本

  • 经机构审查委员会批准、符合《健康保险流通与责任法案》的回顾性研究,纳入106例患者(18个良性、88个恶性病灶),来自两个中心。
  • 2009年2月至2013年3月间行双侧扩散加权成像,使用两台厂商的1.5-T(n=6)或3-T MRI扫描仪,采用单次激发自旋回波平面成像或两次重聚焦双极梯度单次激发涡轮自旋回波读出,b值在0至1000 sec/mm²之间取多个值。
  • 使用Igor(Wavemetrics)和Firevoxel(纽约大学)两款软件包导出组织扩散系数(Dt)、灌注分数(fp)、伪扩散系数(Dp)及其各自的一阶影像组学特征,以组织病理学为参考标准。

诊断标准与关键数值

  • 软件1(Igor)表现最佳的指标为Dt,min(AUC 0.786±0.05)、fp,max(AUC 0.835±0.04)和Dp,max(AUC 0.804±0.05)。
  • 软件2(Firevoxel)表现最佳的指标为Dt,skew(AUC 0.82±0.05)、fp,max(AUC 0.82±0.046)和Dp,max(AUC 0.75±0.06)。
  • 多变量回归纳入Dt,min、Dt,skew、fp,max、Dp,min、Dp,max五个指标,软件1未交叉验证与交叉验证的AUC分别为0.90±0.03和0.90±0.03,软件2分别为0.84±0.04和0.81±0.05。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To evaluate intravoxel incoherent motion (IVIM) biomarkers across different MRI vendors and software programs for breast cancer characterization in a two-site study. Materials and Methods This institutional review board-approved, Health Insurance Portability and Accountability Act-compliant retrospective study included 106 patients (with 18 benign and 88 malignant lesions) who underwent bilateral diffusion-weighted imaging (DWI) between February 2009 and March 2013. DWI was performed using 1.5-T (n = 6) or 3-T MRI scanners from two vendors using single-shot spin-echo echo-planar imaging or twice-refocused, bipolar gradient single-shot turbo spin-echo readout with multiple b values between 0 and 1000 sec/mm2. IVIM parameters tissue diffusivity (Dt), perfusion fraction (fp), pseudo-diffusivity (Dp), and their respective first-order radiomics were derived using two software packages (Igor; Wavemetrics, and Firevoxel; New York University). Bland-Altman analysis compared IVIM metrics from the two software programs. Histopathology was the reference standard, where logistic regressions with adjustments for site compared benign and malignant lesions. Least absolute shrinkage and selection operator (LASSO) penalized multivariable regression was performed first for metrics derived from each parameter separately, and then after incorporating metrics from all three parameters. Area under receiver operating characteristic (ROC) curve (AUC) ± standard error was used to quantify the diagnostic value. Performance was also evaluated using threefold cross-validation of the combined cohort. Results In total, 49 (mean age, 49 years ± 11 [SD]) and 57 (mean age, 48 years ± 10) female patients were enrolled from sites 1 and 2, respectively. Software 1 (Igor) and software 2 (Firevoxel) identified diagnostic biomarkers individually and in multivariable analysis. Tissue diffusivity exhibited the highest software consistency, with coefficients of variation of 4.8% and 2.8% (site 1 and site 2, respectively), followed by perfusion fraction (14.5% and 18.9%) and pseudo-diffusivity (36.9% and 19.8%). The highest performing metrics were Dt,min (AUC, 0.786 ± 0.05), fp,max (AUC, 0.835 ± 0.04), and Dp,max (AUC, 0.804 ± 0.05) for software 1 and Dt,skew (AUC, 0.82 ± 0.05), fp,max (AUC, 0.82 ± 0.046), and Dp,max (AUC, 0.75 ± 0.06) for software 2. Five metrics (Dt,min, Dt,skew, fp,max, Dp,min, Dp,max) were included in the multivariable regression, achieving AUCs of 0.90 ± 0.03 and 0.90 ± 0.03 for software 1, and 0.84 ± 0.04 and 0.81 ± 0.05 for software 2, without and with cross-validation, respectively. Conclusion This study confirmed the translational potential of IVIM biomarkers for breast cancer characterization. Keywords: MR-Diffusion Weighted Imaging, Breast, Technology Assessment Supplemental material is available for this article. © RSNA, 2025.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Sigmund EE, Cho GY, Basukala D, et al. Evaluating Breast Cancer Intravoxel Incoherent Motion MRI Biomarkers across Software Platforms. Radiol Imaging Cancer. 2025. PMID: 40910883. doi:10.1148/rycan.240115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。